Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Effects of a short-term alirocumab administration on the aortic stiffness: preliminary results.

Mauro F, Cinzia F, Arianna R, Marzia T, Gaetano R, Tassone F.

J Geriatr Cardiol. 2019 Oct;16(10):782-784. doi: 10.11909/j.issn.1671-5411.2019.10.001. No abstract available.

2.

Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.

Prezzo A, Cavaliere FM, Bilotta C, Pentimalli TM, Iacobini M, Cesini L, Foà R, Mauro FR, Quinti I.

Leuk Res. 2019 Oct 3;87:106233. doi: 10.1016/j.leukres.2019.106233. [Epub ahead of print]

PMID:
31639635
3.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print]

4.

Palliative Short-course Radiotherapy in Advanced Pelvic Cancer: A Phase II Study (SHARON Project).

Farina E, Macchia G, Siepe G, Zamagni A, Buwenge M, Scirocco E, Cellini F, Deressa BT, Tigeneh W, Uddin KAFM, Sumon MA, Caravatta L, Genovesi D, Mauro FA, Cammelli S, Cilla S, Morganti AG, Deodato F.

Anticancer Res. 2019 Aug;39(8):4237-4242. doi: 10.21873/anticanres.13585.

PMID:
31366511
5.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L.

Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31. No abstract available.

PMID:
31364153
6.

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L.

Hematol Oncol. 2019 Oct;37(4):508-512. doi: 10.1002/hon.2655. Epub 2019 Aug 5. No abstract available.

PMID:
31335982
7.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

8.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.

Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L.

Cancers (Basel). 2019 Jun 26;11(7). pii: E896. doi: 10.3390/cancers11070896.

9.

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L.

Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18.

PMID:
31209327
10.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M.

Haematologica. 2019 Oct;104(10):2053-2060. doi: 10.3324/haematol.2018.205930. Epub 2019 May 16.

11.

Management of STEC Gastroenteritis: Is There a Role for Probiotics?

Giordano M, Baldassarre ME, Palmieri V, Torres DD, Carbone V, Santangelo L, Gentile F, Panza R, Di Mauro F, Capozza M, Di Mauro A, Laforgia N.

Int J Environ Res Public Health. 2019 May 12;16(9). pii: E1649. doi: 10.3390/ijerph16091649. Review.

12.

Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?

Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P.

Gynecol Oncol. 2019 Jul;154(1):138-143. doi: 10.1016/j.ygyno.2019.04.009. Epub 2019 May 9.

PMID:
31079832
13.

Fully immersed: State absorption and electrophysiological effects of the OVO Whole-Body Perceptual Deprivation chamber.

Ben-Soussan TD, Mauro F, Lasaponara S, Glicksohn J, Marson F, Berkovich-Ohana A.

Prog Brain Res. 2019;244:165-184. doi: 10.1016/bs.pbr.2018.10.023. Epub 2019 Jan 12.

PMID:
30732836
14.

Contingent negative variation and P3 modulations following mindful movement training.

Lasaponara S, Glicksohn J, Mauro F, Ben-Soussan TD.

Prog Brain Res. 2019;244:101-114. doi: 10.1016/bs.pbr.2018.10.017. Epub 2019 Jan 3.

PMID:
30732833
15.

Individual EEG alpha profiles are gender-dependent and indicate subjective experiences in Whole-Body Perceptual Deprivation.

Glicksohn J, Berkovich-Ohana A, Mauro F, Ben-Soussan TD.

Neuropsychologia. 2019 Mar 4;125:81-92. doi: 10.1016/j.neuropsychologia.2019.01.018. Epub 2019 Jan 31.

PMID:
30711610
16.

IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.

Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, Barbieri M, Silvestris I, Fabris S, Morabito F, Neri A, Barcellini W, Cortelezzi A.

Leukemia. 2019 Jun;33(6):1519-1522. doi: 10.1038/s41375-018-0344-1. Epub 2019 Jan 11. No abstract available.

PMID:
30635629
17.

Embodied time: Time production in advanced Quadrato and Aikido practitioners.

Ben-Soussan TD, Glicksohn J, De Fano A, Mauro F, Marson F, Modica M, Pesce C.

Psych J. 2019 Mar;8(1):8-16. doi: 10.1002/pchj.266. Epub 2019 Jan 2.

PMID:
30604581
18.

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Guarini A, Peragine N, Messina M, Marinelli M, Ilari C, Cafforio L, Raponi S, Bonina S, Mariglia P, Mauro FR, Gaidano G, Del Giudice I, Foà R.

Br J Haematol. 2019 Feb;184(3):392-396. doi: 10.1111/bjh.15613. Epub 2018 Oct 18.

PMID:
30338509
19.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
20.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Sep;93(9):E216-E219. doi: 10.1002/ajh.25206. Epub 2018 Jul 30. No abstract available.

21.

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Mauro FR, Caputo MD, Rosati S, Pepe S, De Benedittis D, De Luca ML, Foà R.

Expert Rev Hematol. 2018 Aug;11(8):601-611. doi: 10.1080/17474086.2018.1495557. Epub 2018 Jul 18. Review.

PMID:
29969322
22.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W.

Blood. 2018 Aug 2;132(5):547-550. doi: 10.1182/blood-2018-03-835413. Epub 2018 Jun 13. No abstract available.

PMID:
29898955
23.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22. No abstract available.

PMID:
29785734
24.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

25.

Gene mutations in lenalidomide-treated CLL.

Mauro FR, Foà R.

Blood. 2018 Apr 19;131(16):1769-1771. doi: 10.1182/blood-2018-02-830406. No abstract available.

PMID:
29674351
26.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
27.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
28.

Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.

Campennì A, Ruggeri RM, Siracusa M, Pignata SA, Di Mauro F, Vento A, Trimarchi F, Baldari S.

J Endocrinol Invest. 2018 Nov;41(11):1283-1288. doi: 10.1007/s40618-018-0864-6. Epub 2018 Mar 16.

PMID:
29549631
29.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
30.

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.

Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):923-930. doi: 10.1007/s00259-017-3925-8. Epub 2018 Feb 1.

PMID:
29387927
31.

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R.

Ann Oncol. 2018 Apr 1;29(4):966-972. doi: 10.1093/annonc/mdy021.

32.

Are pre-terms born timely and right immunized? Results of an Italian cohort study.

Laforgia N, Di Mauro A, Bianchi FP, Di Mauro F, Zizzi A, Capozza M, Intini S, Gallone MS, Tafuri S.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1398-1402. doi: 10.1080/21645515.2018.1428509. Epub 2018 Feb 15.

33.

White Matter Microstructural Changes Following Quadrato Motor Training: A Longitudinal Study.

Piervincenzi C, Ben-Soussan TD, Mauro F, Mallio CA, Errante Y, Quattrocchi CC, Carducci F.

Front Hum Neurosci. 2017 Dec 7;11:590. doi: 10.3389/fnhum.2017.00590. eCollection 2017.

34.

Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.

Mauro FR, Foà R.

Lancet Oncol. 2018 Jan;19(1):7-8. doi: 10.1016/S1470-2045(17)30910-5. Epub 2017 Dec 12. No abstract available.

PMID:
29246804
35.

Analysis of area level and unit level models for small area estimation in forest inventories assisted with LiDAR auxiliary information.

Mauro F, Monleon VJ, Temesgen H, Ford KR.

PLoS One. 2017 Dec 7;12(12):e0189401. doi: 10.1371/journal.pone.0189401. eCollection 2017.

36.

Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23. No abstract available.

37.

Time Perception and the Experience of Time When Immersed in an Altered Sensory Environment.

Glicksohn J, Berkovich-Ohana A, Mauro F, Ben-Soussan TD.

Front Hum Neurosci. 2017 Oct 6;11:487. doi: 10.3389/fnhum.2017.00487. eCollection 2017.

38.

Clinical relevance of silent red blood cell autoantibodies.

Mauro FR, Trastulli F, Alessandri C, Valesini G, Giovannetti G, Riemma C, Porrazzo M, Pepe S, Colafigli G, Caputo MD, De Propris MS, Guarini AR, Girelli G, Coluzzi S, Foà R.

Haematologica. 2017 Dec;102(12):e473-e475. doi: 10.3324/haematol.2017.177675. Epub 2017 Sep 21. No abstract available.

39.

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.

Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R.

Leukemia. 2018 Feb;32(2):543-546. doi: 10.1038/leu.2017.292. Epub 2017 Sep 19. No abstract available.

40.

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

Vigna E, Martino B, Bacci F, Recchia AG, Mendicino F, Morelli R, Mauro FR, Musolino C, Greco R, Lucia E, Sabattini E, Morabito F, Gentile M.

Chemotherapy. 2017;62(6):350-352. doi: 10.1159/000477796. Epub 2017 Jul 26.

41.

Increased Alpha Band Functional Connectivity Following the Quadrato Motor Training: A Longitudinal Study.

Lasaponara S, Mauro F, Carducci F, Paoletti P, Tombini M, Quattrocchi CC, Mallio CA, Errante Y, Scarciolla L, Ben-Soussan TD.

Front Hum Neurosci. 2017 Jun 12;11:282. doi: 10.3389/fnhum.2017.00282. eCollection 2017.

42.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

43.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

44.

Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M.

Leuk Res. 2017 Jun;57:65-71. doi: 10.1016/j.leukres.2017.02.011. Epub 2017 Feb 27.

PMID:
28292720
45.

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia.

Mauro FR.

Lancet Oncol. 2017 Mar;18(3):270-271. doi: 10.1016/S1470-2045(16)30667-2. Epub 2017 Jan 28. No abstract available.

PMID:
28139406
46.

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.

Mauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, De Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R.

Leuk Lymphoma. 2017 Jul;58(7):1640-1647. doi: 10.1080/10428194.2016.1258698. Epub 2016 Nov 23.

PMID:
27881039
47.

Management of elderly and unfit patients with chronic lymphocytic leukemia.

Mauro FR, Salaroli A, Caputo MD, Colafigli G, Petrucci L, Campanelli M, Ferretti A, Guarini AR, Foà R.

Expert Rev Hematol. 2016 Dec;9(12):1165-1175. Epub 2016 Nov 21. Review.

PMID:
27796157
48.

Association of parathyroid carcinoma and thyroid disorders: A clinical review.

Campennì A, Giovinazzo S, Pignata SA, Di Mauro F, Santoro D, Curtò L, Trimarchi F, Ruggeri RM, Baldari S.

Endocrine. 2017 Apr;56(1):19-26. doi: 10.1007/s12020-016-1147-7. Epub 2016 Oct 15. Review.

PMID:
27744598
49.

Robotic Near-Total Pancreatectomy for Nesidioblastosis after Bariatric Surgery.

Macedo AL, Hidal JT, Marcondes W, Mauro FC.

Obes Surg. 2016 Dec;26(12):3082-3083.

50.

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Blood. 2016 Oct 20;128(16):2093-2095. doi: 10.1182/blood-2016-07-728261. Epub 2016 Aug 22. No abstract available.

Supplemental Content

Support Center